Format

Send to

Choose Destination
Clin Gastroenterol Hepatol. 2016 Mar;14(3):348-354.e17. doi: 10.1016/j.cgh.2015.06.001. Epub 2015 Jun 11.

Defining Disease Severity in Inflammatory Bowel Diseases: Current and Future Directions.

Author information

1
INSERM Unité 954 and Department of Gastroenterology, University of Lorraine, Nancy, France. Electronic address: peyrinbiroulet@gmail.com.
2
Hospital Clinic University of Barcelona, Institut D'Investigacions Biomèdiques August Pi i Sunyer, Centro de Investigación Biomédica en Red en el Área temática de Enfermedades Hepáticas y Digestivas, Barcelona, Spain.
3
Division of Gastroenterology, University of California San Diego, La Jolla, California.
4
Department of Gastroenterology, University Hospital Leuven, Leuven, Belgium.
5
Division of Gastroenterology, Istituto Clinico Humanitas, Milan, Italy.
6
Robarts Research Institute, University of Western Ontario, London, Ontario, Canada.
7
Department of Hepatogastroenterology, Centre Hospitalier Universitaire Régional, Lille, France.
8
Feinberg School of Medicine, Northwestern University, Chicago, Illinois.
9
AbbVie Ltd, Maidenhead, Berkshire, United Kingdom.

Abstract

Although most treatment algorithms in inflammatory bowel disease (IBD) begin with classifying patients according to disease severity, no formal validated or consensus definitions of mild, moderate, or severe IBD currently exist. There are 3 main domains relevant to the evaluation of disease severity in IBD: impact of the disease on the patient, disease burden, and disease course. These measures are not mutually exclusive and the correlations and interactions between them are not necessarily proportionate. A comprehensive literature search was performed regarding current definitions of disease severity in both Crohn's disease and ulcerative colitis, and the ability to categorize disease severity in a particular patient. Although numerous assessment tools for symptoms, quality of life, patient-reported outcomes, fatigue, endoscopy, cross-sectional imaging, and histology (in ulcerative colitis) were identified, few have validated thresholds for categorizing disease activity or severity. Moving forward, we propose a preliminary set of criteria that could be used to classify IBD disease severity. These are grouped by the 3 domains of disease severity: impact of the disease on the patient (clinical symptoms, quality of life, fatigue, and disability); measurable inflammatory burden (C-reactive protein, mucosal lesions, upper gastrointestinal involvement, and disease extent), and disease course (including structural damage, history/extension of intestinal resection, perianal disease, number of flares, and extraintestinal manifestations). We further suggest that a disease severity classification should be developed and validated by an international group to develop a pragmatic means of identifying patients with severe disease. This is increasingly important to guide current therapeutic strategies for IBD and to develop treatment algorithms for clinical practice.

KEYWORDS:

Disease Course; Disease Severity; Inflammatory Bowel Disease

PMID:
26071941
DOI:
10.1016/j.cgh.2015.06.001
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center